Inhibiting the molecular evolution of cancer through HSP90

Oncotarget

Volumn 3, Issue 10, 2012, Pages 1054-1056

  Martins, Ana Sofia ^a   Davies, Faith E ^a   Workman, Paul ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; LENALIDOMIDE; PROTEIN KINASE B;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ASXL1 GENE; CANCER INHIBITION; CANCER PREVENTION; CANCER RISK; CBL GENE; DRUG EFFICACY; EDITORIAL; EZH2 GENE; HUMAN; IDH1 GENE; IDH2 GENE; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MOLECULAR EVOLUTION; MYELODYSPLASTIC SYNDROME; ONCOGENE K RAS; ONCOGENE N RAS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RUNX1 GENE; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; TET2 GENE; TP53 GENE; TUMOR GENE;

EID: 84872815234     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.738     Document Type: Editorial

References (8)

1. Garcia-Manero G. Am J Hematol. 2012; 87: 692-701.
2. Flandrin-Gresta P, Solly F, Aanei CM et al. Oncotarget. 2012
3. Shih AH, Abdel-Wahab O, Patel JP et al. Nat Rev Cancer. 2012; 12: 599-612.
4. Neckers L, Workman P. Clin Cancer Res. 2012;18:64-76.
5. Hostein I, Robertson D, DiStefano F et al. Cancer Res. 2001; 61:4003-9.
6. Flandrin P, Guyotat D, Duval A et al. Cell Stress Chaperones. 2008;13:357-64.
7. Duval A, Olaru D, Campos L et al. Haematologica. 2006; 91:713-4.
8. George P, Bali P, Annavarapu S et al. Blood. 2005;105:1768-76.